A phase one study shows personalised T cell activation induced durable immune responses with manageable toxicity in patients with chronic lymphocytic leukaemia receiving targeted therapy.

A Brossay Lab study reveals how nonclassical CD8+ T cells can be activated by molecules that go undetected by classical CD8+ ...

The orchestration of T cell activation is central to immune defence and self-tolerance. Recent advances have revealed that T cells integrate signals from their antigen receptors alongside a network of ...

The FDA has cleared the investigational new drug (IND) application for NPX372, a first-in-class T-cell engager (TCE) for the ...

NextPoint Therapeutics, a clinical-stage biotechnology company developing a new world of precision therapeutics through its leading scientific work on the novel B7-H7 axis, today announced the ...

What if cancer isn’t unstoppable — but the immune system just isn’t fully awake? Scientists at the University of Southampton ...

CAR T-cell therapy, considered one of the most promising breakthroughs in cancer treatment, works by harnessing the patient’s ...

By David Bautz, PhD NASDAQ:ESLA Business Update On February 9, 2026, Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced that results from the Phase 1 Trial of CD19-ARTEMIS® T cells (EB103) in ...

Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...

Immunotherapy has transformed the field of medicine. In the context of cancer, immune cells become dysregulated and lose the ...